CG Oncology IncNASDAQ:CGON
- LAST PRICE37.1500
- TODAY'S CHANGE (%)-2.5400 (-6.3996%)
- Bid / Lots37.0200/ 6
- Ask / Lots37.1500/ 1
- Open / Previous Close39.6800 / 39.6900
- Day Range
- 52 Week Range
- Volume227,978
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CGON |
|---|---|---|
| 09:32 ET | 1807 | 39.5 |
| 09:33 ET | 3767 | 38.84 |
| 09:35 ET | 100 | 38.81 |
| 09:37 ET | 1530 | 38.92 |
| 09:39 ET | 700 | 39.005 |
| 09:42 ET | 1245 | 38.57 |
| 09:44 ET | 467 | 38.695 |
| 09:48 ET | 300 | 38.645 |
| 09:50 ET | 1900 | 38.975 |
| 09:51 ET | 678 | 38.95 |
| 09:53 ET | 100 | 38.62 |
| 09:57 ET | 533 | 38.59 |
| 10:00 ET | 1900 | 38.37 |
| 10:04 ET | 100 | 38.505 |
| 10:06 ET | 1200 | 38.595 |
| 10:08 ET | 3006 | 38.49 |
| 10:09 ET | 900 | 38.53 |
| 10:11 ET | 700 | 38.44 |
| 10:13 ET | 8905 | 37.995 |
| 10:18 ET | 500 | 37.78 |
| 10:22 ET | 1186 | 37.06 |
| 10:24 ET | 530 | 36.79 |
| 10:26 ET | 6591 | 37.03 |
| 10:27 ET | 3073 | 37.47 |
| 10:29 ET | 1180 | 37.5 |
| 10:31 ET | 650 | 37.92431 |
| 10:33 ET | 200 | 37.955 |
| 10:36 ET | 565 | 38.09 |
| 10:38 ET | 1458 | 38.0825 |
| 10:40 ET | 2300 | 37.91 |
| 10:42 ET | 1322 | 37.955 |
| 10:44 ET | 1600 | 37.985 |
| 10:45 ET | 2698 | 38.045 |
| 10:47 ET | 100 | 38.0475 |
| 10:49 ET | 1649 | 38.08 |
| 10:51 ET | 170 | 38.14 |
| 10:54 ET | 300 | 38.18 |
| 10:56 ET | 2157 | 37.92 |
| 10:58 ET | 300 | 38.06 |
| 11:00 ET | 5064 | 37.98 |
| 11:02 ET | 100 | 38.01 |
| 11:03 ET | 300 | 38.05 |
| 11:05 ET | 200 | 38 |
| 11:07 ET | 523 | 38.06 |
| 11:12 ET | 2537 | 38.04 |
| 11:14 ET | 1839 | 38.225 |
| 11:16 ET | 400 | 38.225 |
| 11:18 ET | 1018 | 38.26 |
| 11:20 ET | 2207 | 38.235 |
| 11:21 ET | 500 | 38.28 |
| 11:23 ET | 600 | 38.29 |
| 11:25 ET | 100 | 38.325 |
| 11:27 ET | 1533 | 38.29 |
| 11:30 ET | 3680 | 38.185 |
| 11:32 ET | 1200 | 38.17 |
| 11:36 ET | 1436 | 38.48 |
| 11:38 ET | 100 | 38.36 |
| 11:39 ET | 100 | 38.47 |
| 11:41 ET | 500 | 38.47 |
| 11:43 ET | 100 | 38.465 |
| 11:45 ET | 566 | 38.365 |
| 11:48 ET | 722 | 38.355 |
| 11:50 ET | 8320 | 38.15 |
| 11:52 ET | 200 | 38.09 |
| 11:54 ET | 1568 | 38.205 |
| 11:56 ET | 1331 | 38.3 |
| 11:57 ET | 1850 | 38.225 |
| 11:59 ET | 700 | 38.2 |
| 12:01 ET | 500 | 37.9 |
| 12:03 ET | 1668 | 37.946 |
| 12:08 ET | 812 | 37.96 |
| 12:10 ET | 1809 | 37.86 |
| 12:12 ET | 782 | 37.88 |
| 12:14 ET | 423 | 37.8 |
| 12:15 ET | 932 | 37.97 |
| 12:17 ET | 800 | 37.815 |
| 12:19 ET | 4708 | 37.72 |
| 12:24 ET | 200 | 37.66 |
| 12:26 ET | 3200 | 37.585 |
| 12:28 ET | 300 | 37.67 |
| 12:30 ET | 100 | 37.7 |
| 12:33 ET | 100 | 37.605 |
| 12:35 ET | 200 | 37.66 |
| 12:39 ET | 900 | 37.595 |
| 12:42 ET | 100 | 37.59 |
| 12:44 ET | 2233 | 37.38 |
| 12:46 ET | 600 | 37.37 |
| 12:48 ET | 100 | 37.32 |
| 12:50 ET | 310 | 37.26 |
| 12:51 ET | 100 | 37.16 |
| 12:53 ET | 100 | 37.16 |
| 12:55 ET | 200 | 37.15 |
| 12:57 ET | 660 | 37.14 |
| 01:00 ET | 100 | 37.01 |
| 01:02 ET | 700 | 37.01 |
| 01:04 ET | 2387 | 37.21 |
| 01:08 ET | 100 | 37.21 |
| 01:09 ET | 100 | 37.205 |
| 01:11 ET | 1400 | 36.98 |
| 01:18 ET | 2500 | 37.085 |
| 01:22 ET | 100 | 37.095 |
| 01:24 ET | 8823 | 37.13 |
| 01:26 ET | 700 | 36.945 |
| 01:27 ET | 1500 | 37.01 |
| 01:29 ET | 100 | 37.01 |
| 01:31 ET | 1194 | 37.15 |
| 01:33 ET | 300 | 37.17 |
| 01:36 ET | 343 | 37.17 |
| 01:38 ET | 300 | 37.15 |
| 01:40 ET | 500 | 37.05 |
| 01:42 ET | 600 | 37.08 |
| 01:44 ET | 400 | 37.025 |
| 01:45 ET | 1000 | 37.065 |
| 01:47 ET | 100 | 37.065 |
| 01:49 ET | 393 | 37.065 |
| 01:51 ET | 1700 | 37.15 |
Today
Press Release: CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates, from 6 hours ago by Dow Jones
6 hours ago by Dow JonesCG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates, from 6 hours ago by Dow Jones
6 hours ago by Dow JonesDJ CG Oncology Price Target Maintained With a $75.00/Share by HC Wainwright & Co., from 7 hours ago by Dow Jones
7 hours ago by Dow Jones
Yesterday
Oct 24, 2024
DJ CG Oncology Initiated at Buy by UBS, from 7:35AM ET on Thursday Oct 24, 2024 by Dow Jones
7:35AM ET on Thursday Oct 24, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
CG Oncology Inc | 2.7B | -31.8x | --- |
Keros Therapeutics Inc | 2.8B | -12.8x | --- |
Soleno Therapeutics Inc | 2.6B | -17.3x | --- |
Scholar Rock Holding Corp | 2.5B | -11.8x | --- |
Dyne Therapeutics Inc | 2.8B | -8.1x | --- |
Geron Corp | 2.5B | -12.6x | --- |
Company Information
CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The Company’s product candidate, cretostimogene is initially in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its lead candidate, BOND-003 is a targeted oncolytic intravesically delivered immunotherapy agent that is in Phase II for the treatment of Bacillus Calmette Guerin (BCG) unresponsive and intermediate risk NMIBC disease. Its other product candidate CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).
Contact Information
- Headquarters
- 400 Spectrum Center Drive, Suite 2040IRVINE, CA, United States 92618
- Phone
- 949-288-6298
- Fax
- 302-531-3150
Executives
- Chairman of the Board, Chief Executive Officer
- Arthur Kuan
- President, Chief Operating Officer
- Ambaw Bellete
- Chief Financial Officer
- Stephen Dipalma
- Chief Medical Officer
- Vijay Kasturi
- Lead Independent Director
- Leonard Post
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.7B |
|---|---|
Revenue (TTM) | $650.0K |
Shares Outstanding | 67.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.17 |
Book Value | $2.91 |
P/E Ratio | -31.8x |
Price/Sales (TTM) | 4,095.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -12,572.92% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
